Diclofenac for Prevention of Post-ERC Pancreatitis
Status:
Not yet recruiting
Trial end date:
2022-03-31
Target enrollment:
Participant gender:
Summary
The study aims at assessing the effectiveness of Diclofenac for prevention of post-ERCP
pancreatitis. It will be undertaken embedded in the Swedish national register for Gallstone
surgery and ERCP (GallRiks). Patients are randomised to Diclofenac prior to the ERCP or no
prophylaxis. GallRiks is used to identify which patients fulfill the eligibility criteria and
which patients develop pancreatitis after the ERCP.